BR0315971A - Método para inibir o desenvolvimento de câncer por inibidores de sintase de ácido graxo - Google Patents

Método para inibir o desenvolvimento de câncer por inibidores de sintase de ácido graxo

Info

Publication number
BR0315971A
BR0315971A BR0315971-0A BR0315971A BR0315971A BR 0315971 A BR0315971 A BR 0315971A BR 0315971 A BR0315971 A BR 0315971A BR 0315971 A BR0315971 A BR 0315971A
Authority
BR
Brazil
Prior art keywords
fatty acid
inhibitors
cancer development
acid synthase
fas
Prior art date
Application number
BR0315971-0A
Other languages
English (en)
Inventor
Francis P Kuhadja
Elizabeth M Jaffee
Craig A Townsend
Original Assignee
Fasgen Llc
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fasgen Llc, Univ Johns Hopkins filed Critical Fasgen Llc
Publication of BR0315971A publication Critical patent/BR0315971A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)

Abstract

"MéTODO PARA INIBIR O DESENVOLVIMENTO DE CâNCER POR INIBIDORES DE SINTASE DE áCIDO GRAXO". A presente invenção refere-se a um método para inibir ou prevenir o desenvolvimento do câncer pela administração de inibidores de sintase de ácido graxo (FAS). Em particular, a presente invenção proíbe ou impede o desenvolvimento do câncer invasivo de lesões pré-malignas (não-invasivas) que expressam FAS. Composições contendo inibidores de FAS da mesma forma são fornecidos, bem como métodos para administrar os inibidores de FAS e composições aos pacientes em necessidades destes.
BR0315971-0A 2002-10-31 2003-10-31 Método para inibir o desenvolvimento de câncer por inibidores de sintase de ácido graxo BR0315971A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42274602P 2002-10-31 2002-10-31
PCT/US2003/034658 WO2004041189A2 (en) 2002-10-31 2003-10-31 A method for inhibiting cancer development by fatty acid synthase inhibitors

Publications (1)

Publication Number Publication Date
BR0315971A true BR0315971A (pt) 2005-09-20

Family

ID=32312552

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0315971-0A BR0315971A (pt) 2002-10-31 2003-10-31 Método para inibir o desenvolvimento de câncer por inibidores de sintase de ácido graxo

Country Status (12)

Country Link
US (1) US20070142456A1 (pt)
EP (1) EP1565180A4 (pt)
JP (1) JP2006507306A (pt)
KR (1) KR20050111573A (pt)
CN (1) CN1728994A (pt)
AU (1) AU2003287380B8 (pt)
BR (1) BR0315971A (pt)
CA (1) CA2503717A1 (pt)
EA (1) EA200500745A1 (pt)
MX (1) MXPA05004390A (pt)
WO (1) WO2004041189A2 (pt)
ZA (1) ZA200503463B (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101007796A (zh) * 2006-01-27 2007-08-01 北京摩力克科技有限公司 新型五元杂环化合物及其制备方法和医疗用途
CN101820757A (zh) 2007-06-01 2010-09-01 普林斯顿大学托管委员会 通过调节宿主细胞代谢途径治疗病毒感染
US8343753B2 (en) 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
EP2217929A4 (en) * 2007-11-13 2011-10-05 Fasgen Inc FATTY ACID SYNTHASE PHOSPHORYL AND TREATMENT OF CANCER
WO2009151910A2 (en) * 2008-05-25 2009-12-17 Wyeth Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
US20100267803A1 (en) * 2008-11-07 2010-10-21 The Research Foundation Of State University Of New York Regulators Of Fat Metabolism As Anti-Cancer Targets
WO2010118324A2 (en) 2009-04-09 2010-10-14 Nuclea Biotechnologies, LLC Antibodies against fatty acid synthase
KR101138460B1 (ko) 2009-10-12 2012-04-26 한국생명공학연구원 항-ｆａｓｎ 자가면역 항체를 포함하는 간암 진단 마커 및 이의 항원을 포함하는 간암 진단용 조성물
WO2011046309A2 (en) * 2009-10-12 2011-04-21 Korea Research Institute Of Bioscience And Biotechnology A diagnostic marker for hepatocellular carcinoma comprising anti-fasn autoantibodies and a diagnostic composition for hepatocellular carcinoma comprising antigens thereof
US8450350B2 (en) 2010-05-05 2013-05-28 Infinity Pharmaceuticals, Inc. Triazoles as inhibitors of fatty acid synthase
EP3159331A1 (en) 2010-05-05 2017-04-26 Infinity Pharmaceuticals, Inc. Tetrazolones as inhibitors of fatty acid synthase
CA2849207A1 (en) * 2010-11-24 2012-05-31 Craig Townsend Methods of screening compounds that are cytotoxic to tumor cells and methods of treating tumor cells using such compounds
CN105168214B (zh) * 2015-08-11 2018-03-13 中国科学院西北高原生物研究所 苄基异喹啉类生物碱的新用途
WO2018170485A1 (en) * 2017-03-16 2018-09-20 The Board Of Trustees Of The Leland Stanford Junior University Diagnostic and therapeutic methods for kras positive cancers

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5759837A (en) * 1989-01-17 1998-06-02 John Hopkins University Chemotherapy for cancer by inhibiting the fatty acid biosynthetic pathway
AU682007B2 (en) * 1992-07-24 1997-09-18 Johns Hopkins University, The Use of inhibitors of fatty acid synthesis for treating cancer
US5539132A (en) * 1994-01-24 1996-07-23 Johns Hopkins University Cerulenin compounds for fatty acid synthesis inhibition
US5981575A (en) * 1996-11-15 1999-11-09 Johns Hopkins University, The Inhibition of fatty acid synthase as a means to reduce adipocyte mass
KR20090031957A (ko) * 1999-11-12 2009-03-30 더 존스 홉킨스 유니버시티 세포내 말로닐 ＣｏＡ의 수준을 증가시킴에 의한 암의 치료방법
EP1235568A2 (en) * 1999-11-12 2002-09-04 The Johns Hopkins University School Of Medicine Depletion of cellular coenzyme-a levels as a means to selectively kill cancer cells
GB0000131D0 (en) * 2000-01-06 2000-02-23 Univ Cardiff Thiolactomycin analogues,compositions containing the same and uses thereof

Also Published As

Publication number Publication date
WO2004041189A3 (en) 2004-12-23
WO2004041189A2 (en) 2004-05-21
AU2003287380A1 (en) 2004-06-07
JP2006507306A (ja) 2006-03-02
CN1728994A (zh) 2006-02-01
KR20050111573A (ko) 2005-11-25
EP1565180A2 (en) 2005-08-24
ZA200503463B (en) 2010-04-28
US20070142456A1 (en) 2007-06-21
EA200500745A1 (ru) 2005-12-29
CA2503717A1 (en) 2004-05-21
EP1565180A4 (en) 2008-02-27
AU2003287380B8 (en) 2009-07-09
MXPA05004390A (es) 2005-11-23
AU2003287380B2 (en) 2009-05-28

Similar Documents

Publication Publication Date Title
BR0315971A (pt) Método para inibir o desenvolvimento de câncer por inibidores de sintase de ácido graxo
Innocenti et al. Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I–XV
BR0317183A (pt) Método de usar compostos de aminocianopiridina como inibidores de proteìna quinase-2 ativada por proteìna quinase ativada por mitógeno
Momeny et al. Effects of silibinin on cell growth and invasive properties of a human hepatocellular carcinoma cell line, HepG-2, through inhibition of extracellular signal-regulated kinase 1/2 phosphorylation
BRPI0514295A (pt) 1, 5-difenilpirazóis
BRPI0510394A (pt) inibidores de 11-beta-hidroxiesteróide desidrogenase tipo 1
BR0317430A (pt) Compostos inibidores de quinase-2 de proteìna ativada por quinase de proteìna ativada por mitógeno
BR9905788A (pt) Derivados de 2-(2-oxo-etilideno)-imidazolidin-4-ona e composições e métodos para a inibição do crescimento de célula anormal que compreendem os referidos derivados
BR112015012295A2 (pt) métodos para tratar um paciente, e, kit para identificar um paciente com câncer
BRPI0409624A (pt) 2-hidróxi-3-diaminoalcanos de benzamida
NZ580226A (en) Dimer compounds as inhibitors of iap
BR0309355A (pt) 2-(2,6-diclorofenil)-diarilimidazóis
WO2007134086A3 (en) Methods of treating fatty liver disease comprising inhibiting glucosphingolipid synthesis
WO2003061768A3 (fr) Utilisation d'un compose inactivant la proteine kinase a dans une composition contenant un milieu cosmetiquement acceptable, pour eclaircir la peau
BRPI0418031A (pt) inibidores de quinase fosfonato-substituìdos
EA200101085A1 (ru) Гидроксамовые кислоты, производные ароматических сульфонов, - ингибиторы металлопротеаз
BRPI0409627A (pt) 2-hidróxi-3-diaminoalcanos de fenacila
BR0213932A (pt) Combinação do inibidor da ciclooxigenase-2/inibidor da desacetilase histona
BRPI0509653A (pt) inibidores cinesina mitótica
BRPI0514868A (pt) composto, composição farmacêutica, uso de um composto, métodos para produzir um efeito inibidor de hdac em um animal de sangue quente, para tratar ou prevenir cáncer em um animal de sangue quente, e para tratar doenças, e, processo para preparar um composto
WO2010039536A3 (en) Sirt4 and uses thereof
WO2008001391A3 (en) Site-specific inhibitors of histone methyltransferase [hmtase] and process of preparation thereof
AR084216A1 (es) Composiciones y metodos para tratar el cancer usando un inhibidor de pi3k e inhibidor de mek, kit
WO2010075287A3 (en) Compounds and methods for the treatment of pain and other diseases
WO2008072952A3 (en) Anti-inflammatory compounds containing compositions for treatment of cancer

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA:INT.CI. A61K 31/34, A61P 35/00

Ipc: A61K 31/34 (2011.01), A61P 35/00 (2011.01)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.